Radionuclide therapy for pancreatic neuroendocrine neoplasms
10.19538/j.cjps.issn1005-2208.2019.09.13
- Author:
Lin QIU
1
;
Hong-cheng SHI
1
Author Information
1. Department of Nuclear Medicine,Zhongshan Hospital,Fudan University Shanghai 200032,China
- Publication Type:Journal Article
- Keywords:
somatostatin;
somatostatin analogue;
somatostatin receptors;
pancreatic neuroendocrine neoplasms;
peptide receptor radionuclide therapy
- From:
Chinese Journal of Practical Surgery
2019;39(09):934-938
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic neuroendocrine neoplasms(pNENs)are the most common neuroendocrine tumors.For early local pNENs,surgery is the main therapeutic strategy and the tumor can be removed completely.But for those pNENs that cannot be surgically removed or have undergone distant metastasis,peptide receptor radionuclide therapy(PRRT)can be chosen as a first-line therapeutic strategy as pNENs overexpress somatostatin receptors.In recent years,clinical trials and studies on the use of PRRT in pNENs have been increasing rapidly.Many reports have confirmed the efficacy of 90 Y and 177 Lu-labeled somatostatin analogue in pNENs patients.
